Cergentis is a spin-off from the Royal Dutch Academy of Sciences and its Hubrecht Institute and has developed the Targeted Locus Amplification (TLA) Technology. Uniquely, the TLA Technology enables targeted complete Next Generation Sequencing of genes of interest. The technology enables complete gene sequencing and the detection of all point mutations and structural variants. The TLA Technology presents unique advantages in genetic research, genetic diagnostics and the development and implementation of personalized medicine. In this presentation Max van Min (CEO) will sketch the history of Cergentis, describe the TLA Technology and how Cergentis aims to contribute to increasing the quality and utility of Next Generation Sequencing.
Max van Min, Cergentis